Close
Achema middle east
swop processing & packaging

Nuvo Research announces launch of Pliaglis in Europe

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Quantum Computing Advances Make Way for Lifesaving Therapies

The fact is that there is something very profoundly...

Specialty pharmaceutical company Nuvo Research has announced the launch of Pliaglis (lidocaine and tetracaine) cream 7%/7% by Galderma in Europe.

Galderma has worldwide marketing rights for Nuvo’s Pliaglis, a topical local anesthetic cream indicated for the production of local dermal anaesthesia preceding dermatological procedures in adults.

Pliaglis leverages Nuvo’s phase-changing technology that allows the formation of a pliable peel on the skin on exposure to air.

Galderma Aesthetic and Corrective Center of Excellence managing director Didier Leclercq said, “Pliaglis really sets a new standard in topical anesthetics, and is a great complementary product in our already comprehensive Aesthetic portfolio in Europe. “

Nuvo pain group president Dr. Bradley Galer said, “Galderma has an excellent launch plan for the countries of Europe to introduce the benefits of Pliaglis to physicians who provide aesthetic services to their patients.”

The launch of the product in Canada and certain Central American, South American and Asian countries is anticipated in 2014 and 2015. Pliaglis was already introduced into Argentina and the US markets in 2011 and 2013 respectively.

 

Latest stories

Related stories

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Quantum Computing Advances Make Way for Lifesaving Therapies

The fact is that there is something very profoundly...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »